{"database": "lobbying", "table": "lobbying_activities", "rows": [[1341331, "ca34715c-abee-4e7a-a1ee-927395fe8b5a", "Q4", "COVIDIEN LP", 319778, "COVIDIEN LP", 2012, "fourth_quarter", "PHA", "Issues involving controlled substance and pain and addiction drugs generally;  H.R. 2119: Ryan Creedon Act of 2011To amend the Controlled Substances Act to require practitioners to obtain particular training or special certification, approved by the Attorney General, on addiction to and abuse of controlled substances and appropriate and safe use of controlled substances in schedule II, III, IV, or V, and for other purposes; Issues related to acetaminophen.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)", null, 470000, 0, 0, "2013-01-18T08:35:02.197000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1341331"], "units": {}, "query_ms": 0.370368012227118, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}